...
首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Poor Prognosis, Relapsed or Refractory CD19+Follicular Lymphoma: Prolonged Remissions Relative to Antecedent Therapy
【24h】

Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Poor Prognosis, Relapsed or Refractory CD19+Follicular Lymphoma: Prolonged Remissions Relative to Antecedent Therapy

机译:嵌合抗原受体改性T细胞针对预后,复发或难治性CD19 +卵瘤的患者中的CD19(CTL019):相对于前一种治疗的延长的剩余

获取原文
获取原文并翻译 | 示例
           

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号